Safety PP 1

合集下载

工艺安全管理Process-SafetyPPT课件

6
OSHA
Occupational Safety & Health Administration U.S. Department of Labor美国劳工部职业安全与健康管理局（OSHA）
10 10
▪ Overview of Prevention Program Regulations预防项目规章概述 ▪ Management Systems管理系统
• Emergency Planning and Response
• Compliance Audits
• Trade Secrets
• 机械完整性 • 动火作业许可证 • 变更管理 • 事故调查 • 应急计划和反应 • 合规性审核 • 商业秘密
12
What is Process Safety? 什么是工艺安全？
13
工艺安全
化工行业这一更为广阔的技术背景下的 “系统安全” 关注于化学生产技术的安全 “个人安全”、 “工作场所安全”也很重要
但是，这些风险的管理工作非常不一样个人安全做得好并不能保证工艺安全也做得很好
114
Personal Safety 个人安全
• Hazard recognition by workers • 工人对危害的认知
• Contractor employees must be included 承包商职工必须包括在内
25 25
REQUIREMENTS 具体要求
• Employers shall develop a written plan of action regarding the implementation of the employee participation required by this paragraph [1910.119(c) (1)]

安全生产翻译英文缩写

安全生产翻译英文缩写Work safety is the cornerstone of a productive and prosperous society. In order to improve work safety and prevent accidents, many organizations and government agencies have developed safety production guidelines and systems. These guidelines and systems are often referred to by various abbreviations. In this article, we will provide translations and explanations for some common work safety abbreviations in Chinese.1. 安全生产 General Work Safety (AQSC)The term 安全生产 (An Quan Sheng Chan) translates to General Work Safety in English. It refers to the overall management and procedures put in place to prevent accidents and ensure the safety of workers in a workplace. This abbreviation is commonly used in government documents and safety regulations.2. 安全评价 Safety Evaluation (AQPJ)安全评价 (An Quan Ping Jia) refers to the process of assessing and evaluating the safety risks and hazards present in a workplace. It involves identifying potential dangers and implementing measures to prevent accidents and injuries. This abbreviation is often used in safety assessment reports and safety audits.3. 现场管理 Site Management (XCG)现场管理 (Xian Chang Guan Li) refers to the management and supervision of a work site to ensure that all safety regulations and procedures are followed. This includes monitoring the use of personal protective equipment, maintaining equipment and machinery, and implementing safety measures. This abbreviationis commonly used in construction and industrial safety.4. 隐患排查 Hidden Danger Investigation (YHPC)隐患排查 (Yin Huan Pai Cha) refers to the process of identifying and resolving hidden risks and hazards in a workplace. It involves conducting inspections and assessments to identify potential dangers and taking corrective actions to eliminate them. This abbreviation is often used in safety inspection and audit reports.5. 应急救援 Emergency Response and Rescue (YJJY)应急救援 (Ying Ji Jiu Yuan) refers to the procedures and protocols that are implemented in the event of an emergency or accident. It involves immediate response and rescue actions to minimize the impact and ensure the safety of workers. This abbreviation is commonly used in emergency response plans and training materials.6. 操作规程 Operation Procedures (CZGC)操作规程 (Cao Zuo Gui Cheng) refers to the step-by-step instructions and guidelines that are followed when carrying out specific tasks or operations. This includes procedures for using machinery, handling hazardous materials, and performing other tasks that may pose risks. This abbreviation is often used in work instructions and operating manuals.7. 作业票 Work Permit (ZYPP)作业票 (Zuo Ye Piao) refers to a permit or document that authorizes a worker to perform a specific job or task. It is used to ensure that workers are qualified and trained to perform the tasksafely. This abbreviation is commonly used in industries such as construction, oil and gas, and chemical manufacturing.In conclusion, these abbreviations are commonly used in the context of work safety to provide a concise and standardized way of referring to various aspects of safety production. By understanding these abbreviations, workers and employers can communicate effectively and promote a culture of safety in the workplace.。

pp和ps材料哪种安全

pp和ps材料哪种安全在生活中，我们经常会接触到pp和ps材料，它们被广泛应用于日常生活用品、工业制品等领域。

然而，很多人对于这两种材料的安全性存在疑虑，不知道该如何选择。

那么，pp和ps材料哪种更安全呢？接下来，我们将从环保性、毒性、稳定性等方面进行分析，帮助大家更好地了解这两种材料。

首先，我们来看环保性。

pp材料是一种环保型材料，它可以100%回收利用，对环境没有污染。

而ps材料在生产过程中会释放出有害气体，对环境造成一定的影响。

因此，从环保的角度来看，pp材料更加安全。

其次，我们需要考虑毒性问题。

pp材料是一种无毒材料，不会释放有害物质。

而ps材料在高温下会释放出苯类物质，对人体健康有一定危害。

因此，从毒性的角度来看，pp材料更加安全。

再者，我们来谈谈稳定性。

pp材料具有较好的稳定性，不易受化学物质侵蚀，使用寿命较长。

而ps材料在阳光下容易老化变脆，使用寿命较短。

因此，从稳定性的角度来看，pp材料更加安全。

总的来说，pp材料在环保性、毒性和稳定性方面都比ps材料更加安全可靠。

因此，在选择日常生活用品、食品包装等产品时，建议优先选择pp材料制成的产品，以保障自身和家人的健康安全。

当然，虽然pp材料相对更加安全，但在使用过程中仍然需要注意一些细节。

比如，不要将pp材料制品暴露在高温环境下，避免接触酸性、碱性物质等。

只有正确使用和保养，才能更好地发挥pp材料的优势，确保安全使用。

综上所述，pp材料相比ps材料在安全性上具有明显优势，尤其在环保性、毒性和稳定性方面更加可靠。

因此，在选择材料时，我们应该更加倾向于选择pp材料，以保障自身和环境的安全。

希望本文能够帮助大家更好地了解pp和ps材料的安全性，做出明智的选择。

PP化学物质安全技术说明书

PP化学物质安全技术说明书MATERIAL SAFETY DATA SHEET（PP）1. Chemical Product and Company IdentificationProduct Name: PPProduct Use: Used according to manufacturer's directions. Compounding.2. Hazards IdentificationGHS Classification:This product is not hazardous under the criteria of U.S. Occupational Safety and Health Standard 29 CFR 1910 Subpart Z and United Nations GHS Parts 2, 3, and 4. Potential Health Effects:Eye: Dust and process vapors may irritate eyes.Skin: Exposure to molten resin may cause thermal burns.Inhalation: Dust and process vapors may cause respiratory tract irritation. Ingestion: Not Applicable3. Composition / Information on IngredientsName: PolypropyleneSynonyms: PP, Polypropylene Homo-polymer/Random-copolymer/Impact-copolymer CAS No:Homo-polymer: 009003-07-0,Random-copolymer: 009010-79-1,Impact-copolymer: 106565-43-9Hazard Ingredients: None4. Emergency & First-Aid MeasuresRoutes of Exposure:Inhalation: Immediately take the person out into fresh air. If any irritation to the respiratory tract persists, seek medical care. Skin Contact: Wash with soap and water.Eye Contact: Wash with water.Ingestion: Not applicable.5. Fire-Fighting MeasuresExtinguishment: Foam, dry chemicals, water, CO2.Special Procedures: None required. Use misted water.Personal Fire-Fighting Equipment: No special equipment is required.Unusual Hazards: The product is combustible and dust may form an explosive mix.6. Accidental Release MeasuresEmergency personal protection equipment: Dust mask.Precautions to avoid environmental damage:Keep the material from entering a waterway or sewage main. It floats.Clean-up: Sweep and recover the material for reuse or recycling.Waste disposal: In an authorized household or industrial waste deposit.7. Precautions for Safe Handling & StorageGeneral Procedures: Keep away from heat, sparks and flame.Handling: Ground and bond containers when transferring material.Storage: This product may react with strong oxidizing agents and should not be stored near such materials. Store boxes and bags of material in areas protected with automatic sprinklers.Storage Temperature: Store in a cool place below 60°C (140°F).Electrostatic Accumulation Hazard:Material may accumulate static charges during transfers, ground and bond containers when transferring material.8. Exposure Controls / Personal ProtectionEngineering Controls: Provide adequate room ventilation at the extruder to minimize exposure to process vapors. Eliminate ignition sources duringrepair and maintenance operations.Breathing protection: A dust mask for polypropylene in the form of dust.Hand protection: Leather or cloth gloves.Eye protection: Safety goggles.Ventilation: Appropriate natural ventilation.9. Physical and Chemical PropertiesPhysical state: Solid Explosive properties: UnknownOdor: Slight waxy odor Self-ignition temperature: 380-460oCConcentration: 100% Steam pressure at 20oC: Not applicableMelting Point: 140~170oC Steam density (air = 1): 0.965 at 21.1oCpH: N/A Specific gravity (water = 1): 0.90Boiling Point: It decomposes. Solubility in water: InsolubleFlash point: 440 oC Volatile (% by volume): Not applicableDecomposition temperature: >400oC Flame propagation speed: Unknown10. Stability and ReactivityChemical Stability: StableChemical Incompatibility: The product is eaten away by chlorine and strong oxidants. Conditions to avoid: It is degraded by heat and sunlight unless protected by antioxidants.Hazardous Combustive Products: Not available.Hazardous Polymerization: Impossible.11. Toxicological InformationAcute Toxicity: None suggested.Chronic or long-term toxicity: Not available.Local Effects: Local irritation by abrasion.Allergic reaction: Not available.12. Ecological InformationInstability: Not applicable.Persistence/Degradability: Like plastic in the long term.Environmental Precautions: It must be disposed of by incineration or in an authorized waste deposit.13. Disposal ConsiderationsElimination of the product in waste: reuse, recycling, incineration or authorized dump. Elimination of containers/packing: reuse, recycling, authorized dump.14. Transport InformationSpecial Shipping Notes:This product is not regulated by DOT, IMO, IATA, Canadian DG and associatedregulations, ADR or RID.15. Regulatory InformationThis product must be carried according to environmental laws governing the transport ofon-hazardous substances.16. Other InformationThe data contained in this informational sheet were obtained from reliable sources. Theinformation furnished is the information currently available on the product. The use of thisinformation and of the products is beyond the supplier’s control. The user is responsiblefor determining the conditions for safe use of the product.。

聚丙烯 R200P 化学品安全技术说明书

(MATERIAL SAFETY DATA SHEET)存档日期2015. 01. 01Polypropylene R200PPage1 / 7制造厂商株式会社晓星地址蔚山广域市南区处容路487番路66(680-140)电话号码+82-52-208-9311FAX +82-52-208-9320负责部门龙渊1工厂PP 生产组(该资料根据产业安全保健法第41条规定起草)1.化学产品与公司相关信息1)产品名:聚丙烯TOPILENE R200P 2)产品的推荐用途与使用限制①产品推荐用途:泛用塑料原料②产品使用限制:无相关资料3)制造商/供应商/流通企业信息2.有害·危险性1)有害·危险性分类:无对应内容2)包括预防措施文件在内的警告标示项目①图片文字:不需要②信号符号:不需要③有害·危险文件:不需要④预防措施文件-预防:不需要-应对措施:不需要-保管:不需要-废弃:不需要3)为包含在有害·危险性分类标准的其他有害危险性:NFPA 指数(0-4):保健=1,火灾=1,反应性=03.组成成分名称与组成物质名称俗名(惯用名称)CAS 编号含量(wt%)乙二醇-丙烯共聚体含有1-丙烯，共聚体,乙烯(共聚聚丙烯)9010-79-1>99添加剂--< 1※全部构成成分名称与含量的相关事项根据产业安全保健法第41条第2款和施行规则第92条-2第2款内容可视做公司商业机密。

(MATERIAL SAFETY DATA SHEET)存档日期2015. 01. 01Polypropylene R200P Page 2 / 7 4.急救措施要领1)进入眼睛时․与物质接触时，要用流动的水冲洗20分钟以上․请马上就近就医2)与皮肤接触时․与物质接触时，马上用流动的水冲洗20分钟以上․去除被污染的衣物与鞋子，并隔离放在不能接触到的地方․再次使用之前，将衣物与鞋子完全清洗干净․请马上就近就医3)吸入身体时․请向医疗急救求救․移动到有新鲜空气的地方․出现呼吸苦难时，需要吸氧․呼吸困难时，采取人工呼吸，立即向医生就诊4)误食用时․如失去意识，不要喂食任何食物․立即向医生就诊5)其他就医注意事项․医护人员需对该物质有所了解并且采取保护措施5.爆炸、火灾时应对措施1)适当的(不恰当的)灭火剂:可使用粉末灭火剂，二氧化碳，水，一般泡沫灭火剂，大型火灾时，可使用一般灭火剂与微细喷雾2)与化学物质反应出现的特殊有害性-火灾与爆炸危险:由于特殊加热物质(合成树脂类)有引起轻微火灾危险，粉尘/空气混合物质有可能发生火灾或者爆炸-燃烧时发生有害物质:热分解产物为碳氧化物3)灭火时需要陪带的保护器具和预防措施․如可在不危险的情况下进行，将容器移动离开火灾地点․向外露的物质喷射高压水柱，并防止飞散․为后续处理需筑造灾防․为后续处置，需要预备灭火用的灭火用水․对周边火灾使用恰当的灭火剂․避免吸入燃烧产生物质․避免站在低洼地带需要背风站立(MATERIAL SAFETY DATA SHEET)存档日期2015. 01. 01Polypropylene R200P Page 3 / 7 6.外露事故的应对方法1)为保护人体所需要的措施和保护器具․去除任何可燃点火源․如不危险，要停止外露․需要留意避免的物质和条件․对污染空间进行通风换气․不要用手接触外露物质，或者在上面行走․防止粉尘形成․外露时，需要将可能受影响的地区隔离，将所有可能受到影响的所有人都撤离到安全的地点․只允许配戴恰当个人保护装备的人才允许进入外露地点2)为保护环境采取的必要措施․防止进入水道，下水口，地铁，密闭空间等3)净化与去除方法․将散落的Pellet或者Powder用真空吸尘装备或铁锹，回收到合适的回收桶和容器当中7.取放与保管方法1)安全取放要领․避免与皮肤直接接触․有接触后要彻底清洗․注意要避免的物质和条件․在有爆炸危险的地方，要防止静电产生，为了接触Pellet或Powder时防止静电产生，需要装备接地․为防止粉尘的发生与飞散，当飞散时需要通过局部排气装置进行通风换气2)安全保管方法․在完全密闭的容器中保管，并粘贴适当的标签․需要在去除水分，凉爽干燥的场所保管8.防止外露、个人保护装备1)化学物质的外露标准，生物学的外露标准等․韩国规定:无相关资料․ACGIH规定:无相关资料․生物学外露标准:无相关资料2)适当的工业管理․为了在自然通风不够充分的地方，为最大限度防止粉尘的发生，采用局部排气装置等进行通风，或采用其他技术抑制․如浓度达到爆炸危险，需要安装防爆设备和换气设备(MATERIAL SAFETY DATA SHEET)存档日期2015. 01. 01Polypropylene R200P Page 4 / 7․确认作业过程符合劳动部许可标准与外露标准的要求3)个人保护装备-呼吸系统保护․请配戴符合外露物质物理化学特性的必须通过韩国产业安全保健工团认证的保护装备-手，身体保护․为了保护手，皮肤等部位，需要配戴有耐化学性保护的手套和保护衣-眼睛保护․需要配戴保护眼睛所需的防止化学物质的护眼罩或护眼镜․安装方便工作人员使用的可用来进行应急清洗的设施(冲洗式)9.物理化学性特性1)外观:不透明的无色或白色固体2)气味:无味3)气味临界值:无相关资料4)pH:无相关资料5)固化温度/液化温度：130∼170℃　6)沸腾起始点和沸腾温度范围:无相关资料7)燃点:无相关资料8)蒸发速度:无相关资料9)可燃性(固体):无相关资料10)可燃或爆炸范围的上限/下限温度:无相关资料11)蒸汽压:无相关资料12)溶解度:无相关资料13)蒸汽密度:无相关资料14)比重:0.88∼0.92Kg/L(at20℃)15)n-正辛醇/水分配系数:无相关资料16)自燃温度:400℃17)分解温度:无相关资料18)粘度:无相关资料19)分子量:>10,000(MATERIAL SAFETY DATA SHEET)存档日期2015. 01. 01Polypropylene R200P Page 5 / 7 10.安全性与反应性1)化学安全性:常温常压下安全2)有害反应可能性:常温常压下不会产生有害综合反应3)需要避免的条件:避免可以产生热量，火焰，火花等其他货源。

安全生产隐患的英文缩写

安全生产隐患的英文缩写安全生产隐患的英文缩写大致有以下几个：1. HAZAP（Hazards and Operability Study）隐患与可操作性研究。

它是一种系统化的方法，用于在设计、建造或修改工厂、化工厂、电厂、石油天然气工厂、航天航空系统、火车、高速公路系统或其他复杂系统中，发现和评估各种可操作性问题和隐患。

2. EOP（Emergency Operating Procedures）紧急操作程序。

紧急操作程序是指在工业安全事故和突发事件发生时，为保障人身安全、较好地控制和处理事故或事件而制订的各种应急操作规程。

3. PPE（Personal Protective Equipment）个人防护装备。

个人防护装备是一种佩戴在身体上，以保护工作人员免受潜在伤害的器具和装备。

例如，头盔、耳塞、安全鞋、防护眼镜、防护面具、安全手套等。

4. JHA（Job Hazard Analysis）工作危害分析。

工作危害分析（JHA）是一种通过识别和评估工作中的潜在危害，制定控制措施来保护工作人员免受潜在伤害的系统性过程。

5. LOTO（Lockout/Tagout）断电/标记。

（Lockout）是指使用机械设备等锁住能源或动力源，以确保在维修、保养或检修期间，机器无法启动。

在某些情况下，还会使用标签（tagout）来提醒其他人此设备正在维修中，不能被启动。

6. MSDS（Material Safety Data Sheet）物质安全数据表。

物质安全数据表是提供关于一种特定物质的危险性、储存、使用和处置信息的文件。

它为工作人员提供有关物质的安全操作指南和应急处理程序。

7. HAZOP（Hazard and Operability）and FMEA（Failure Mode and Effects Analysis）危险及可操作性分析和失效模式及影响分析。

危险及可操作性分析（HAZOP）和失效模式及影响分析（FMEA）是两种常用于评估过程安全性和可靠性的方法。

Dexibuprofen pharmacologytherapeutic uses and safety

In ammopharmacology,V ol.11,No.4–6,pp.371–383(2003)ÓVSP2003.Also available Dexibuprofen:pharmacology,therapeutic uses and safetyS.T.KAEHLER1;¤,W.PHLEPS1and E.HESSE21Medical Department,Gebro Pharma GmbH,A-6391Fieberbrunn,Austria2Research and Development Department,Gebro Pharma GmbH,Fieberbrunn,AustriaReceived14May2003;accepted27July2003Abstract—Dexibuprofen is the single pharmacologicallyeffective enantiomer of rac-ibuprofen.Rac-ibuprofen and dexibuprofen differ in their physico-chemical properties,in terms of their pharmaco-logical properties and their metabolic pro les.Several clinical trials and post-marketing surveillance studies were performed to broaden the ndings on dexibuprofen.In the last5years4836patients have been exposed to dexibuprofen in clinical trials and PMS trials.Only in3.7%of patients adverse drug reactions have been reported and3serious adverse drug reactions(0.06%)were observed.In the dose ratio of1:0.5(rac-ibuprofen vs.dexibuprofen)at least equivalent ef cacy was proven in acute mild to severe somatic and visceral pain models.Dexibuprofen has proven at least comparable ef cacy to diclofenac,naproxen and celecoxib and has shown a favourable tolerability.The results suggest that dexibuprofen processed in a special crystal form is a safe and effective treatment for different pain conditions.Key words:Dexibuprofen;pharmacology;therapeutic uses;safety;dose ratio;rac-ibuprofen.1.INTRODUCTIONNonsteriodal anti-in ammatory drugs(NSAIDs)like rac-ibuprofen are effective for the relief of pain and their use is widespread(Dionne and McCullagh,1998; Evans,1996;Rainsford,1999).Rac-ibuprofen,which contains equal quantities of R.¡/-ibuprofen and S.C/-ibuprofen,has been used as an anti-in ammatory and analgesic agent for over30years.S.C/-Ibuprofen,or dexibuprofen,is the pharma-cologically effective enantiomer of rac-ibuprofen.Rac-ibuprofen and dexibuprofen differ in their physico-chemical properties(Leising et al.,1996).Furthermore,the two enantiomers of rac-ibuprofen are different in terms of their pharmacological properties and their metabolic pro les.On the rationale basis that a fraction of the dose of R.¡/-ibuprofen undergoes“metabolic inversion”to yield S.C/-ibuprofen,¤To whom correspondenceshould be addressed.Tel.:(43-5354)5300-0;Fax:(43-5354)5300-743; e-mail:stefan.kaehler@gebro.c om372S.T.Kaehler et al.it has been argued that a dose of1:0.75(rac-ibuprofen vs.dexibuprofen)would be needed to obtain comparable pharmacodynamic effects.On the other hand,inver-sion is not instantaneous,the extent is variable,depends on dosing situation and is reduced in patients experiencing acute pain.Several clinical trials and post-marketing surveillance studies were performed to broaden the ndings on dex-ibuprofen.Attention was directed to dose nding,pharmacokinetics,pharmaco-dynamics,special indications and safety in humans.Nineteen clinical trials were conducted according to GCP(in operation since1996)and12were earlier clinical trials.In these31clinical trials and in6post-marketing surveillance trials more than 12000patients were treated with dexibuprofen processed in a special crystal form.2.PHARMACOLOGYDexibuprofen in a special crystal form and rac-ibuprofen differ in their physico-chemical properties,due to their different crystal binding energy,they have different melting points and values for the heat of fusion.Furthermore,dexibuprofen has a solubility twice as high as that of the racemate(Leising et al.,1996).Therefore,it is concluded that dexibuprofen and rac-ibuprofen are two inherently different solid-state materials.Dexibuprofen was classi ed as new chemical entity and,therefore, has a different ATC classi cation code(Table1).Pharmacodynamic differences between enantiomers arise from enantioselective interactions with the chiral macromolecules which constitute the biological recep-tors.Typically,both enantiomers will elicit similar pharmacological effects but one will be more active than the other.It is widely accepted that NSAIDs exert the majority of their pharmacological and toxicological effects by speci cally inhibit-ing the binding of arachidonic acid to the cyclooxigenase sub-unit of prostaglandine synthetase.Thereby they are preventing the formation of the various prostaglandins. On this basis a useful index of the relative anti-in ammatory activities of the in-dividual enantiomers of a chiral NSAID may be obtained in vitro by comparing their effects on cyclo-oxygenase.Where such comparisons have been made,activ-ity has been found to reside almost exclusively with the enantiomer possessing the Table1.Physico-chemical propertiesDexibuprofen Rac-ibuprofen Space group P21=c P21Density(g/cm3) 1.098 1.110 Melting point(±C)52.1§0.375.3§0.3 Heat of fusion(J/g)91§1125§2 Solubility in water at37±C(mg/100ml)11.8 4.8 Solubility in HCl at pH1.5and37±C(mg/100ml)9.61 4.65CAS-No.51146-56-615687-27-1 ATC classi cation M01A E14M01A E01Pharmacology of dexibuprofen373 Table2.Relative potencySubstance Relative potencyS:R(eudismic ratio)RS:SRac-ibuprofen>1000.50Flurbiprofen2000.50Naproxen1330.63Indoprofen>1000.55S-con guration.The eudismic ratio,which is de ned as the activity of the more ac-tive enantiomer(eutomer)relative to that of the less active enantiomer(distomer), frequently exceeded100.When the inhibitory activity of the racemate was mea-sured,it was usually about half of the S-enantiomer,suggesting that the activity of the racemate is due solely to the S-enantiomer(Table2).It has been found that rac-ibuprofen and other profens elicit pharmacological effects via mechanisms which are independent of cyclooxygenase inhibition.Some of these effects include the ability to inhibit leucotriene production,to inhibit in ammatory oedema by an action on polymorphonuclear leucocytes,to reduce sulphated glycosaminoglycan synthesis in articular cartilage in vitro,to upregulate a cyclin/CDK inhibitor to inhibit proliferation of lung cancer cells in vitro(partially COX-dependent),to inhibit nitric oxide synthesis via inhibition of iNOS induction, to inhibit mitochondrial¯-oxidation of fatty acids and to bind selectively to plaques associated with Alzheimer’s disease and dissolve them(Morihara et al., 2002;Rainsford,1999).The clinical signi cance of these and other partially prostaglandin-independent effects is yet to be rmly established.Dexibuprofen is rapidly(maximum plasma concentration after2h)and exten-sively absorbed after oral ingestion.It is suggested that the absorption of dexibupro-fen,as of most drugs from the gastrointestinal tract,is a passive process governed primarily by the physico-chemical properties of the drug.Since this absorption process seems to be dependent on the physico-chemical properties of the drug,the used special crystal form of dexibuprofen may play a fundamental role for the in-terpretation of experimental and clinical data.The administration of dexibuprofen with a meal delays the time to reach maximum concentrations(from2.1h after fasting conditions to2.8h after non-fasting conditions)and decreases marginally the maximum plasma concentrations(from20.6to18.1¹g/ml),which is of no clinical relevance.On the other hand,food has no effect on the extent of absorption.A linear dose–response relationship was shown over the dose range from200to 400mg(Table3).NSAIDs are extensively bound to plasma albumin and the fraction unbound is typically less than1%.The unbound fraction of S.C/-ibuprofen is40–60% greater than that of R.¡/-ibuprofen(fu0.6%vs.fu0.4%).Each enantiomer displayes a concentration-dependent plasma protein binding and is able to displace its optical antipode from plasma binding sites after administration of rac-ibuprofen374S.T.Kaehler et al.Table3.Summary of pharmacokinetic parameters for dexibuprofen200mg300mg400mgC max(mg/l)12.416.424.1t max(h) 2.1 2.8 2.2AUC(mg¢h/l)49.266.496.3parison of metabolic pro le of rac-ibuprofen and dexibuprofen.(Evans,1992,1996).Distribution into and out of synovial uid,cutaneous exudates and CSF is slow.In synovial uid smaller uctuations have been reported compared to those observed in the plasma,which may explain the fact that many NSAIDs are effective when given at dosing intervals which exceed their plasma half-lives.The enantiomers of rac-ibuprofen are metabolised by oxidative routes,with the metabolites undergoing subsequent glucuronidation,to varying extents,prior to excretion.Several profens are involved in unusual metabolic events for which substrate stereochemistry plays a vital rule.The encircled area(Fig.1)shows the metabolic pro le of S.C/-ibuprofen when it is taken as the single enantiomer. The chiral inversion of R.¡/-ibuprofen occurs via the formation of thioester with coenzyme A.This intermediate also serves to introduce R.¡/-ibuprofen into the pathways of lipid metabolism,resulting in the formation of“hybrid trigylcerides”in which the R.¡/-ibuprofen moiety takes place of an endogenous fatty acid. Chiral inversion has been substantiated for a large number of2-arylpropionic acids and involves the transformation of the R-enantiomer to the correspond-Pharmacology of dexibuprofen375Figure2.Pharmacokinetic pro le of dexibuprofen vs.rac-ibuprofen.Plot of plasma concentration vs.time.Data are presented as mean§SEM.Dexibuprofen300mg( lled circles)and rac-ibuprofen 400mg(open squares).ing S-enantiomer.Currently there is no strong evidence to suggest that the re-verse reaction occurs to any signi cant extent.Some NSAID effects shown for R.¡/-ibuprofen in animals may be due to chiral inversion or to presence of the S-enantiomer as impurity.In humans,the fraction of a dose of R.¡/-ibuprofen in-verted,is on average50%.However,the extent of chiral inversion varies between individuals;for example,in osteoarthritis patients being treated with rac-ibuprofen, the fractional inversion of R.¡/-ibuprofen varied between35and85%(Rudy et al.,1992).Factors that have been suggested or demonstrated to in uence the chi-ral inversion of R.¡/-ibuprofen after dosing with the racemate include formulation type,other drugs and disease state.In uence of age,genetics or diet are until now unknown.Moreover,chiral inversion is not instantaneous,the extent is variable, depends on dosing situation and is,e.g.,reduced in patients experiencing acute pain(Jamali and Kunz-Dober,1999).The impact factors,such as other diseases, on the extent of inversion remain largely unexplored.It is speculative,but possi-bly R.¡/-ibuprofen might be capable of inhibiting the effects of S.C/-ibuprofen on COX or might impair the movement of S.C/-ibuprofen into the sites of action. Indeed,this hypotheses support the importance of clinical data in establishing the376S.T.Kaehler et al.effective dose of S.C/-ibuprofen.On the rationale basis that a fraction of the dose of R.¡/-ibuprofen undergoes“metabolic inversion”to yield S.C/-ibuprofen,it has been argued that to obtain comparable pharmacodynamic effects a dose of0.75:1 (dexibuprofen vs.rac-ibuprofen)would be needed.This rationale is supported as shown in Fig.2by pharmacokinetic data.However,suprisingly,clinical trials sup-port a0.5:1dose ratio.3.THERAPEUTIC USESRac-ibuprofen and dexibuprofen have a long and well-established record of being a safe and effective therapy in a considerable range of chronic arthritic and non-arthritic states,and in treatment of acute pain,in ammatory and febrile states.Its merits are that it has a wide range of tolerability.Both are also being investigated for potential therapeutic use in a number of conditions where in ammatory responses and other,in some cases as yet undetermined,mechanisms of the drug are being exploited.There is clinical evidence that dexibuprofen provides faster onset and greater analgesia than rac-ibuprofen,but without decreased duration of activity or greater incidence of adverse reactions(Dionne and McCullagh,1998).In the oral surgery model of dental pain the relative ef cacy of dexibuprofen versus rac-ibuprofen was compared.It was reported that400mg of dexibuprofen provided better analgesic ef cacy than400mg of the racemate.Both drugs were superior to placebo. Surprisingly,200mg of dexibuprofen provided a more rapid onset of analgesic action than400mg of the racemate and provided better pain relief over the rst 3h after dosing(Dionne and McCullagh,1998).This nding was unexpected in that,because of the inversion process,one would expect400mg of rac-ibuprofen to generate the equivalent of about300mg of dexibuprofen,and therefore a better clinical response.In one study that can be regarded as one of the dose nding type,it was shown that with reference to the initial dose of rac-ibuprofen,52%of dexibuprofen and99%of the racemate were suf cient to obtain the same clinical results in patients suffering from chronic in ammatory and degenerative rheumatic diseases(Klein et al.,1992).In the dose ratio of0.5:1(dexibuprofen vs.rac-ibuprofen)at least equivalent ef cacy was shown in acute mild to severe somatic and visceral pain models like lumbar vertebral syndrome,rheumatoid arthritis, distorsion of the ankle joint,ankylosig spondylitis,activated ostheoarthritis of the hip,ostheoarthritis of the knee,postoperative dental pain or dysmenorrhoe.These effects were provided at daily doses of dexibuprofen ranging from200mg to 1800mg with most at600to1200mg daily(Fig.3).Dexibuprofen,400mg and200mg three times a day,showed a positive dose–re-sponse relationship in improving the WOMAC OA index.Dexibuprofen400mg compared to rac-ibuprofen800mg showed a borderline superiority for dexibuprofen 400mg.Surprisingly,even dexibuprofen200mg was equivalent to800mg rac-ibuprofen in a three times a day dosing schedule(Singer et al.,2000).Also,inPharmacology of dexibuprofen377parison of ef cacy in acute mild to severe somatic and visceral pain models. Dexibuprofen vs.rac-ibuprofen,in double-blind,randomized,comparative clinical trials in a dose ratio of0.5:1.Data are presented as Mann–Whitney point estimate with its95%lower bound of con dence interval(LB/CI).The benchmarks0:29=0:71D proven relevant inferiority/superiority, 0:36=0:64D proven non-inferiority/superiority,0:44=0:56D non-relvant inferiority/superiority and0:50D equivalence are presented as horizontal lines.Non-inferiority is proven by LB/CI values>0:36.the oral surgery model of dental pain a positive dose–response relationship for dexibuprofen was found.Furthermore,dexibuprofen200mg possesses at least an equivalent analgesic effect as rac-ibuprofen in the double dose(Fig.4).In double-blind,active controlled clinical trials in patients suffering from activated painful osteoarthritis of the knee or hip dexibuprofen has proven at least comparable ef cacy to diclofenac,naproxen and celecoxib by an favourable or comparable tolerability after the15-day treatment period(Fig.5).Recently,it was reported that dexibuprofen in a dose of400mg twice a day had an incidence of gastrointestinal complaints of8.11%,whereas celecoxib in a dose of200mg per day had a value of 9.46%(Hawel et al.,2003).4.SAFETYThe factors that are associated with a variation in the level of risk of gastrointestinal bleeding or ulcer perforation and the extent to which the risk apparently varies between different members of the class of NSAIDs have also been investigated. The comparative toxicity of rac-ibuprofen and other NSAIDs led to the claim that378S.T.Kaehler et al.Figure4.Dose–response relationship of dexibuprofen in dental pain.Dose-related effects of the analgesic drugs on pain relief are presented as SPID.Each mark represents the median with its95% con dence interval(CI).¤P<0:05dexibuprofen400mg vs.dexibuprofen200mg;¤P<0:05 dexibuprofen400mg vs.rac-ibuprofen400mg;¤P<0:05dexibuprofen400mg vs.placebo.Allactive treatments were superior to placebo.this particular drug is safer than other NSAIDs(Langman et al.,1994).In doses of 1600mg or less it has been associated with a lower degree of toxicity than other NSAIDs,and this has been consistent across the endoscopic studies,the analysis of voluntary adverse reaction reports and the major controlled epidemiological studies (Rainsford,1999).However,there is also evidence that,when rac-ibuprofen is used in doses of2400mg or more,it has a similar toxicity to other commonly used drugs,such as naproxen.Furthermore,the combined usage of corticosteroids and NSAIDs has been shown to induce gastrointestinal complications10-times more frequently than NSAIDs alone,even though there is no de nite association between the use of corticosteroids and development of ulcers.The risk of complications is increased proportionally to the dose of NSAID given and is inversely related to the duration of therapy(Tseng and Wolfe,2000).The commonest problem, however,with rac-ibuprofen and other NSAIDs is dyspepsia.Dyspeptic symptoms, including heartburn,anorexia,abdominal pain and distention,have been reportedPharmacology of dexibuprofen379parison of ef cacy in acute mild to moderate somatic pain models.Dexibuprofen vs.diclofenac,naproxen or celecoxib in double-blind,randomized,comparative clinical trials.Data are presented as Mann–Whitney point estimate with its95%lower bound of con dence interval (LB/CI).The benchmarks0:29=0:71D proven relevant inferiority/superiority,0:36=0:64D proven non-inferiority/superiority,0:44=0:56D non-relevant inferiority/superiority and0:50D equivalence are presented as horizontal lines.Non-inferiority is proven by LB/CI values>0:36.in5–20%of patients taking NSAIDs(Tseng and Wolfe,2000).Calculations of the odds ratio where rac-ibuprofen was directly compared with paracetamol yielded data for the gastrointestinal system as a whole with an odds ratio of1.00.With the individual gastrointestinal adverse events,the odds ratio for abdominal discomfort was0.45,for nausea1.03,for heartburn0.77and for abdominal pain3.1.This last result suggests that rac-ibuprofen may have been responsible for more abdominal discomfort than was paracetamol,but the data were not signi cantly different.This was borne out when all of the data for the two drug groups were compared,which yielded an OR value of1.35(Rainsford,1999).In an animal model of bethanechol induced gastric irritation it was shown that after7h rac-ibuprofen had up to4-times more lesions than dexibuprofen. The authors suggest that the greater toxicity caused by rac-ibuprofen could have clinical implications(Janjikhel and Bricker,1999).In the last5years4836pa-tients have been exposed to dexibuprofen in clinical trials and post-marketing surveillance trials.Only in5.2%of patients a total number of318adverse events have been reported.Out of these,3.7%of patients experienced249adverse events related to dexibuprofen.Moreover,only3serious adverse drug reactions(0.06%) were observed.The majority of adverse events and adverse drug reactions were380S.T.Kaehler et al.Figure6.Cumulative incidence of adverse drug reactions in clinical trials and post-marketing surveillance trials(n D4836patients).Probability for patients experiencing adverse drug reactions in comparison to exposure time to treatment with dexibuprofen.gastrointestinal(60%),of which most were symptomatic gastrointestinal reactions (dyspepsia,nausea,etc.).It is postulated that the incidence of adverse drug reactions is pronounced in the rst10to30days of exposure and maintained thereafter. Moreover,this nding is supported by the cumulative incidence of adverse drug reactions after simple pooling of our clinical trials and post marketing surveillance trials data.This low number of3.7%of patients may be explained by the possible under-reporting in post-marketing surveillance trials(Fig.6).Indeed,80%of the reported adverse events occured in the rst20to40days of exposure.Furthermore, spontaneous reports and reports from clinical trials have comparable curves.As mentioned before,the majority of adverse drug reactions were gastrointestinal (Fig.7).In general,rac-ibuprofen has been regarded as being inactive as an inhibitor of the5-lipoxygenase pathway.However,studies by Villanueva et al.(1993), Vanderhoek and Bailey(1984)and Vanderhoek et al.(1984)showed that LTB-4 production is inhibited.Recently,in an in vitro study it was shown that100¹M of dexibuprofen inhibited the biosynthesis of LTB-4by approximately30%.ItPharmacology of dexibuprofen381Figure7.Relative cumulative incidence of adverse drug reactionsin clinical trials and post-marketing surveillance trials(n D4836patients).Relative probability for patients experiencing adverse drug reactions in comparison to exposure time to treatment with dexibuprofen.Dashed line,spontaneous reports;continuous line,clinical trials.is suggested that the mechanism of the reduction of LTB-4production is by the inhibition of5-lipoxygenase activity.This nding could be one explanation for the favourable balance between therapeutic ef cacy and tolerability for dexibuprofen. Matrixmetalloproteinases(MMPs)play a fundamental role in the control of cartilage physiology.Rheumatic diseases are characterized by the progressive destruction of cartilage,a process that is under the control of various factors. Moreover,in the MMP family,stromelysin(MMP-3)is considered to play an important role in this destructive process.The surrogate marker MMP-3is not altered during therapy with dexibuprofen in the recommended maximum daily dose of1200mg over a3-week treatment period.Similar results were observed for MMP-1,MMP-8and MMP-9.Since there are slight decreases in the higher values,it is suggested that dexibuprofen may delay the cartilage destruction progress (Fig.8).Further controlled clinical trials are indicated.5.CONCLUSIONSThe results suggest that dexibuprofen processed in a special crystal form is a safe and effective treatment for different pain conditions.Furthermore,it can be stated that the use of S.C/-ibuprofen is metabolically cleaner and R.¡/-ibuprofen might contribute to adverse effects as shown in the bethanechol-induced gastric irritation model.The removal of R.¡/-ibuprofen avoids the involvement in lipid metabolism, S.C/-ibuprofen avoids variability compared to rac-ibuprofen which underlies a382S.T.Kaehler et al.Figure8.Correlation of parison of individual patient data at baseline (day1)and on treatment(after15–21days).Each patient may be presented by one mark in the gure.variable chiral inversion.Bridging studies versus rac-ibuprofen,studies versus other NSAIDs including celecoxib con rm a good relative ef cacy pro le.The results demonstrate that in a dose ratio of0.5:1dexibuprofen is at least equally effective and safe as rac-ibuprofen.REFERENCESDionne,R.A.and McCullagh,L.(1998).Enhanced analgesia and supression of plasma¯-endorphin by the S.C/-isomer of ibupropfen,Clin.Pharmacol.Ther.63,694–701.Evans,A.M.(1992).Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steriodal anti-in ammatory drugs,Eur.J.Clin.Pharmacol.42,237–256.Evans,A.M.(1996).Pharmacodynamics and pharmacokinetics of the profens:enantioselectivity, clinical implications,and special reference to S.C/-ibuprofen,J.Clin.Pharmacol.36,S7–S15.Pharmacology of dexibuprofen383 Hawel,R.,Klein,G.,Singer,F.,et al.(2003).Comparison of the ef cacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip,Int.J.Clin.Pharmacol.Ther.41,153–164.Jamali,F.and Kunz-Dober,C.M.(1999).Pain-mediated altered absorption and metabolism of ibuprofen:an explanationfor decreased serum enantiomer concentrationafter dental surgery,Br.J.Clin.Pharmacol.47,391–396.Janjikhel,R.K.and Bricker,J.D.(1999).Stereoselective disposition of sustained release microphers of ibuprofen enantiomers in rats:II.Acute gastrointestinaltoxicity,Drug Deliv.6,163–170. Klein,G.,Neff,H.,Kullich,W.,et al.(1992).S.C/versus racemic ibuprofen,Lancet339,681. Langman,M.J.S.,Weil,J.and Wainright,P.(1994).Risks of bleeding peptic ulcer associated with individual non-steriodal anti-in ammatory drugs,Lancet343,1075–1078.Leising,G.,Resel,R.,Stelzer,F.,et al.(1996).Physical aspects of dexibuprofen and racemic ibuprofen,J.Clin.Pharmacol.36,3S–6S.Morihara,T.,Chu,T.,Ubeda,O.,et al.(2002).Selective inhibition of A¯42production by NSAID R-enantiomers,J.Neurochem.83,1009–1012.Rainsford,K.D.(Ed.)(1999).Pharmacology and toxicology of ibuprofen,in:Ibuprofen,a critical bibliographic review,pp.145–275,Taylor&Francis,London.Rudy,A.C.,Bradley,J.D.,Ryan,S.I.,et al.(1992).Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients,Ther.Drug Monitoring14,464–470.Singer,F.,Mayrhofer,F.,Klein,G.,et al.(2000).Evaluation of the ef cacy and dose-response rela-tionship of dexibuprofen(S.C/-ibuprofen)in patients with osteoarthritisof the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index.Int.J.Clin.Pharmacol.Ther.38, 15–24.Tseng,C.-C.and Wolfe,M.M.(2000).Nonsteriodal anti-in ammatory drugs,Adv.Gastroenterol.84, 1329–1344.Vanderhoek,J.Y.and Bailey,M.J.(1984).Activation of a15-lipoxygenase/leukotriene pathway in human polymorphonuclear leucocytes by the anti-in ammatory agent ibuprofen,J.Biol.Chem.259,6752–6756.Vanderhoek,J.Y.,Ekborg,S.L.and Bailey,M.J.(1984).Effects of cell growth,differentiation,and transformation:clinical involvement of leucotrienes,J.Allergy Clin.Immunol.74,412–416. Villanueva,M.,Heckenberger,H.,Palmer,S.M.,et al.(1993).Equipotent inhibition by R-.¡/-, S-.C/-and racemic ibuprofen of human polymorphonuclear cell function in vitro,Br.J.Clin.Pharmacol.35,235–242.。

PP 环境因素危险源辨识及风险评价表

可能导致的伤害（事故）
1
烘干
移印机/设备操作员
转移烘干零件时未戴防护用品
灼烫
2
印刷
移印机/设备操作员
接触稀释剂、油墨等化学药品时未戴防护用品
职业病
3
印刷/烘干
油墨/稀释剂/设备操作油墨、稀释剂随意乱放、
员
遇明火引起火灾
火灾
类别 S/H
S
作业条件危险性评价风险 L E C D 等级
6 6 3 108 3
作员
裸露在外
8
烘干
烘干机/操作员
人员未离开烘箱，就开始加热
职业病触电
灼烫
H
6 6 7 252 4 每日点检，发现问题及时通知部门负责人
是
S
3 6 7 126 3
制定设备维护计划，加强日常点检
是
S
3 6 15 270 1
加热前确认烘箱内是否有人，对烘箱进行改进，从内部可以打开烘箱，加强安全教育
是
是
S
3 6 1 18 1
下料工序的员工必带手套
是
S
1
6
3
18
1
机器运行时，员工禁止触摸机器上部，工作需要时，必须带劳保用品
是
H
6
6
7 252 4
机器安装排风系统，并每天对排风系统进行点检
是
S
3 6 3 54 2
对吹风管包裹隔热布，对员工进行培训
是
S
3 6 1 18 1 制定授权人员名单，对员工进行培训。
是
S
3 6 3 54 1
在升降车底部安装顶快
是
S
3 6 3 54 2 更换新的车轱辘并对烤架定期检查及时修理

磷酸一铵安全技术说明书英文

SAFETY DATA SHEETSAccording to Globally Harmonized System of Classification andLabelling of Chemicals (GHS) - Sixth revised editionLIdentification1.1GHS Product identifierProduct name ammonium dihydrogen phosphate1.2Other means of identificationProduct number- Other names azanium,dihydrogen phosphate1.3Recommended use of the chemical and restrictions on useIdentified uses For industry use only. Agricultural chemicals(non-pesticidal),Flameretardants,Intermediates,Processing aids, nototherwis listed,Processing aids, specific topetroleum productiUses advised against no data available1.4Supplier's detailsCompanyAddressTelephone Fax1.5Emergency phone numberEmergency phone numberService hours Monday to Friday, 9am-5Pm (Standard time zone: UTC/GMThours).2.Hazard identification2.1 Classification of the substance or mixtureNot classified.2.2 GHS label elements, including precautionary statementsHazard statement(s) none Pictogram(s)Signal wordNo symbol. No signal word.Precautionary statement(s)Prevention noneResponse noneStorage noneDisposal none2.3Other hazards which do not result in classificationnoneposition/information on ingredients3.1Substances4.First-aid measures4.1Description of necessary first-aid measuresGeneral adviceConsult a physician. Show this safety data sheet to the doctor in attendance.If inhaledIf breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.In case of skin contactWash off with soap and plenty of water. Consult a physician.In case of eye contactRinse thoroughly with plenty of water for at least 15 minutes and consult a physician.If swallowedNever give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.4.2Most important symptoms/effects, acute and delayedInhalation of monoammonium form causes irritation of mucous membranes; with diammonium form, ammonia vapors in closed area cancause pulmonary edema and asphyxia. Contact with solid or with ammonia gas causes irritation of eyes and skin. (USCG, 1999)4.31ndication of immediate medical attention and special treatment needed, if necessary/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, startartificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. PerformCPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, leanpatient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration.Keep patient quiet and maintain normal body temperature.Obtain medical attention. /Ammonia and related compounds/5.Fire-fighting measures5.1Extinguishing mediaSuitable extinguishing mediaUse water spray, alcohol-resistant foam, dry chemical or carbon dioxide.5.25pecific hazards arising from the chemicalSpecial Hazards of Combustion Products: Toxic and irritating fumes of ammonia and oxides of nitrogen may form in fires. (USCG, 1999)5.35pecial protective actions for fire-fightersWear self-contained breathing apparatus for firefighting if necessary.6.Accidental release measures6.1Personal precautions, protective equipment and emergency proceduresUse personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8.6.2Environmental precautionsPrevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided.6.3Methods and materials for containment and cleaning upPick up and arrange disposal. Sweep up and shovel. Keep in suitable, closed containers for disposal.7.Handling and storage7.1Precautions for safe handlingAvoid contact with skin and eyes. Avoid formation of dust and aerosols. Avoid exposure - obtain special instructions beforeuse.Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2.7.2Conditions for safe storage, including any incompatibilitiesStore in cool place. Keep container tightly closed in a dry and well-ventilated place.8.Exposure controls/personal protection8.1Control parametersOccupational Exposure limit valuesno data availableBiological limit valuesno data available8.2Appropriate engineering controlsHandle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.8.31ndividual protection measures, such as personal protective equipment (PPE)Eye/face protectionSafety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriategovernment standards such as NIOSH (US) or EN 166(EU).Skin protectionWear impervious clothing. The type of protective equipment must be selected according to the concentration and amount of thedangerous substance at the specific workplace. Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique(without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves afteruse in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.Respiratory protectionWear dust mask when handling large quantities.Thermal hazardsno data available9.Physical and chemical propertiesPhysical state white crystallinepowderColour White, tetrahedral crystalsOdour OdorlessMelting point/ freezing 190°CpointBoiling point or initial158°C at 760 mmHgboiling point and boilingrangeFlammability no data available Lower and upper explosion no data available limit / flammabilitylimit Flash point Auto-ignition temperature Decomposition temperature pH Kinematic viscosity Solubility Partition coefficient n-octanol/water (log value) Vapour pressure Density and/or relative densityRelative vapour density no data available nodata available no data availablepH of 0.2 Molar aq soln:no data availableIn water:368 g/L(20 °C) no dataavailableno data available 1.803no data available4.2Particle characteristics no data available10.Stability and reactivity10.1Reactivityno data available10.2Chemical stabilityStable in air10.3Possibility of hazardous reactionsDecomposition of sodium hypochlorite takes place within a few seconds with the following salts:ammonium acetate, ammonium carbonate, ammonium nitrate, ammonium oxalate, and ammonium phosphate[Mellor 2 Supp. 1:550 1956]. Several liquid ammonium phosphate fertilizer tanks have ruptured due toinadequate tank design and maintenance. The failure of these tanks were not considered hazardous,except that the failure of these tanks caused failure of nearby tanks of chemicals such as ammonia(anhydrous) and phosphoric acid. (EPA Chemical Safety Alert)10.4Conditions to avoidno data available10.5Incompatible materialsA self-propagating reaction can occur when either sodium bicarbonate or potassium bicarbonate-based dry chemical extinguishing agent is mixedwith monoammonium phosphate dry chemical extinguishing agent. Moisture will accelerate the reaction. Products are water, ammonia, carbon dioxide and various solid substances. In a fire extinguisher the pressure developed will blow out the valve.10.6Hazardous decomposition productsDecomposes to ammonia and phosphoric acid when heated.ll.Toxicological informationAcute toxicity•Oral: LD50 Rat oral 5750 mg/kg bw•Inhalation: no data available•Dermal: no data availableSkin corrosion/irritationno data availableSerious eye damage/irritationno data availableRespiratory or skin sensitizationno data availableGerm cell mutagenicityno data availableCarcinogenicityno data availableReproductive toxicityno data availableSTOT-single exposureno data availableSTOT-repeated exposureno data availableAspiration hazardno data available12.Ecological information12.1Toxicity•Toxicity to fish: no data available•Toxicity to daphnia and other aquatic invertebrates: no data available•Toxicity to algae: no data available•Toxicity to microorganisms: no data available12.2Persistence and degradabilityno data available12.3Bioaccumulative potentialno data available12.4Mobility in soilno data available12.5Other adverse effectsno data available13.Disposal considerations13.1Disposal methodsProductThe material can be disposed of by removal to a licensed chemical destruction plant or by controlled incineration with flue gas scrubbing. Do not contaminate water, foodstuffs, feed or seed by storage or disposal. Do not discharge to sewer systems.Contaminated packagingContainers can be triply rinsed (or equivalent) and offered for recycling or reconditioning.Alternatively, the packaging can be punctured to make it unusable for other purposes and then be disposed of in a sanitary landfill. Controlled incineration with flue gas scrubbing is possible for combustible packaging materials.14.Transport information14.1UN NumberADR/RID: Not dangerous goods.IMDG: Not dangerous goods. IATA: Not dangerousgoo(14.2UN Proper Shipping NameADR/RID: unknownIMDG: unknownIATA: unknown14.3Transport hazard class(es)ADR/RID: Not dangerous goods.IMDG: Not dangerous goods. IATA: Not dangerousgoo(14.4Packing group, if applicable。

施工常用英语单词

接火盆防火毯灭火器氧气瓶乙炔瓶氩气瓶
常用英汉对照
argon
英语
Nitrogen Natural gas
fuel oil grease Packing Mark of Goods attention keep dry up flat ,stow level s side ( end ) up rd against damp hoisting here to be stowed under heavy cargo land on end keep upright handle with care ,no rough handling inflammable rishable fragile plosives rrosives zardous goods; dangerous cargo caution fire
Lanyard
Eye-Loop Shock absorber Strap Self-Locking karabiner Snap-Hook working platforms grating platform Steel structure pipe rack life line tag line put on barricade warning signs Height limit sign load chart webbing sling shackle Lastmoment Lifting Radius wind speed
Page 4 of 19
氩气氮
天然气
汉语
燃料油润滑脂货物装箱标志小心勿受潮必须平放此边（端）向上防潮此处吊起怕压竖着放勿倒置小心轻放易然物品/易爆物易腐蚀品易碎物品爆炸品腐蚀品危险品当心火灾

D4GL-2FFA-A;D4GL-2DFG-A;D4GL-4HFG-A;D4GL-4DFG-A;中文规格书,Datasheet资料

D4GL Door-mounting Accessory with Lockout Key to Prevent Workers from Becoming Trapped inside Hazardous Area•The vertical D4GL Guard Lock Safety-door Switch can be easily mounted on 40 × 40 mm aluminum frames. •The plastic material makes the Slide Key suitable for lightweight doors.ConfigurationD4GL-SK10-LKBe sure to read the “Safety Precautions” on page 5 and the “Precautions for All Safety Door Switches”.D4GL (sold separately)D4GL-SK10-LKFeaturesThe lockout key prevents workers from becoming trapped without using a padlock.Note:Using two-color LEDs enables confirming whether the door is open or closed and locked or unlocked.Example: D4GL-2DFA-A with mechanical lock and solenoid releaseClo s e door.Locked (power notsu pplied to s olenoid)The s lide h a ndle i s clo s ed.Clo s e door.Locked (power not su pplied to s olenoid)The s lide h a ndle i s clo s ed.The s lide h a ndle c a n b e p u lled.Open door.The s lide h a ndle i s open.When the s lide h a ndle i s open, the locko u t key c a n b e p u lled reg a rdle ss of whether power i s b eing su pplied to the s olenoid or not.Open door.The s lide h a ndle i s open.Left doorDoor Opening to the Left.The s lide h a ndle i s s ec u red a t the po s ition s hown in the fig u re.A worker holding the locko u t key will not b e tr a pped locked in s ide the h a z a rdo us a re a b y a nother per s on.Open door.The s lide h a ndle doe s not move.The s lide h a ndle i s open.If the locko u t key i s not mo u nted, the s lide h a ndle will not move a nd the door will not clo s e.Locko u t KeyDo not t u rn the key as in the fig u re ab ove if the s lide h a ndle i s clo s ed.The h a ndle-s h a ped fixt u re m a ke s it e as y to us e the Door S witch.Att a ch the su ppliedc au tion l ab el s for di s pl a y.Ordering InformationNote:1.The Door Switch is not included. Select the Door Switch depending on the necessary number of contacts and the conduit size.The contents are provided as a total set, individual contents cannot be ordered separately.2.Perform risk assessment for the equipment in question, configure relay units and other safety circuits, and use properly.Applicable Door SwitchesAppearanceSpecificationsContentsModelApplicable Door SwitchWeight: Approx. 0.6 kg Mechanical durability: 20,000 operations min.Slide Key: 1 (not yet mounted)D4GL mounting plate: 1Door Switch special mounting screws: 4D4DS-K1 (operation key): 1D4DS-K1 special mounting screws: 2Lockout keys: 2Lockout key strap: 1Caution labels (stickers): 2 sheets (Englishand Japanese)D4GL-SK10-LK D4GL•The two-color (orange/green) LED indicators enablechecking whether the door is locked and the key is inserted.•With gold-plated contacts used as standard, general loads and microloads are supported.Guard LockSafety-door SwitchD4GLList of ModelsRelease key typeSolenoid voltage and indicator typeLock and release typesContact configuration(door open/closed detection switch andlock monitor switch contacts)Conduit opening Model StandardSolenoid: 24 VDC Orange/green LED: 24 VDCMechanical lock, Solenoid release1NC/1NO+1NC/1NOPg13.5D4GL-1AFA-A G1/2D4GL-2AFA-A M20D4GL-4AFA-A 1NC/1NO+2NCPg13.5D4GL-1BFA-A G1/2D4GL-2BFA-A M20D4GL-4BFA-A 2NC+1NC/1NOPg13.5D4GL-1CFA-A G1/2D4GL-2CFA-A M20D4GL-4CFA-A 2NC+2NCPg13.5D4GL-1DFA-A G1/2D4GL-2DFA-A M20D4GL-4DFA-A 2NC/1NO+1NC/1NOPg13.5D4GL-1EFA-A G1/2D4GL-2EFA-A M20D4GL-4EFA-A 2NC/1NO+2NCPg13.5D4GL-1FFA-A G1/2D4GL-2FFA-A M20D4GL-4FFA-A 3NC+1NC/1NOPg13.5D4GL-1GFA-A G1/2D4GL-2GFA-A M20D4GL-4GFA-A 3NC+2NCPg13.5D4GL-1HFA-A G1/2D4GL-2HFA-A M20D4GL-4HFA-A Solenoid lock,Mechanical release1NC/1NO+1NC/1NOPg13.5D4GL-1AFG-A G1/2D4GL-2AFG-A M20D4GL-4AFG-A 1NC/1NO+2NCPg13.5D4GL-1BFG-A G1/2D4GL-2BFG-A M20D4GL-4BFG-A 2NC+1NC/1NOPg13.5D4GL-1CFG-A G1/2D4GL-2CFG-A M20D4GL-4CFG-A 2NC+2NCPg13.5D4GL-1DFG-A G1/2D4GL-2DFG-A M20D4GL-4DFG-A 2NC/1NO+1NC/1NOPg13.5D4GL-1EFG-A G1/2D4GL-2EFG-A M20D4GL-4EFG-A 2NC/1NO+2NCPg13.5D4GL-1FFG-A G1/2D4GL-2FFG-A M20D4GL-4FFG-A 3NC+1NC/1NOPg13.5D4GL-1GFG-A G1/2D4GL-2GFG-A M20D4GL-4GFG-A 3NC+2NCPg13.5D4GL-1HFG-A G1/2D4GL-2HFG-A M20D4GL-4HFG-ADimensions(Unit: mm)mounting holesD4GL-SK10-LK (Close door.)40 ×Safety PrecautionsRefer to the “Precautions for All Switches” and “Precautions for All Safety Door Switches”.•Do not drop the Product. Doing so may prevent the Product from functioning to full capacity.•Mount the Product securely to prevent it from falling. Otherwise, injury may occur.•Do not attempt to disassemble or modify the Switch. Doing so may cause the Switch to malfunction.•Make sure that the gap between the shot bolt and the guide is ±0.5 mm. Otherwise, excessive wear or damage may cause malfunction.•To ensure safety, do not operate the Switch with anything other than the Slide Key Unit.•Your hand may be injured by being pinched between the Operation Key and Switch when closing the door with your hand on the Product.•Be careful to avoid pinching your hand when operating the Slide Handle.•Do not impose a force of exceeding 1 N·m when operating the Lockout Key. Otherwise, the Product may be damaged and may not operate properly.To prevent damage, attach the supplied labels for display near the Product.•Do not force the slide handle to move when the lockout key is not inserted. Doing so may damage the product and make operation impossible.•Do not force the slide handle to move when the door is locked. •Do not close the door with the shot bolt removed. Doing so may damage the product and make operation impossible.•Turn the Lockout Key to the "SLIDE LOCK" position and remove it when opening the door to prevent a third party from operating the Slide Handle.•The durability of the Switch varies considerably depending on the switching conditions. Always confirm the usage conditions by using the Switch in an actual application, and use the Switch only for the number of switching operations given in the performance specifications.•The user must not maintain or repair equipment incorporating the Switch. Contact the manufacturer of the equipment for any maintenance or repairs required.•Refer to the D4GL Guard Lock Safety-door Switch Datasheet and Instruction Sheet about storage conditions, ambient conditions, Switch details, and handling methods.•Do not apply excessive force in the direction of the slide. This may damage the product and cause it to malfunction.•Do not force the switch or cable. Thismay damage the product. The cableshould be fixed at a point separatefrom the switch.•This product is for D4GL Guard Lock Safety-door Switch only. This product cannot be used with any other manufacturer's doorswitches.•Use the Slide Handle in the direction A or B in the following figure.•Loose screws may result in malfunction. Use washers and tighten the screws to the specified torques. Mount the Slide Base at four points with screws. Adding adhesive is recommended forpreventing the screws from loosening.Also, when mounting the Product to a door for disable-prevention purposes, purchase and use tamper-resistant screws. Appropriate Tightening TorqueTechnical Specifications•Do not store the Switch where corrosive gases (e.g., H2S, SO2,NH3, HNO3 or Cl2) or dust is present, or in locations subject to hightemperature or humidity.•Perform maintenance inspections periodically.•When the lockout key is attached to your wrist, be careful that thestrap does not get stuck in equipment.Do not use this product mounted so that it slidesvertically. This may cause malfunction, resulting inpersonal injury.Do not insert the operation key with the door open.Devices may start to operate, resulting in injury.Precautions for Safe UsePrecautions for Correct UseSlide Key mounting screw (M6) 6.0 to 7.0 N·mOperation key special mounting screw (screws supplied) 2.4 to 2.8 N·mSwitch special mounting screw (screws supplied) 1.3 to 1.5 N·mAmbient operating temperature−10 to 55°C (with no icing)Ambient operating humidity95% max.Mechanical durability20,000 operations min.WeightApprox. 0.6 kg (not including D4JL GuardLock Safety-door Switch)NomenclatureDifferences between Lockout Key and Trapped Key (Reference)•When mounting the operation key, line up the inside edges of the long operation key holeswith the outer edges of the slidehandle as in the following figure to ensure easy position adjustment.•Use the supplied special screws to mount the operation key and D4GL Guard Lock Safety-door Switch.To tighten the screws, use the tip of a flat-head screwdriver on the screw heads as shown in the following figure.•The special screws cannot be removed once they are tightened.Lockout keyTrapped key(Refer to information on theD4JL-@@@A-@7-@@)Closing the doorThe door cannot be closed unless the lockout key is inserted in the slide and turned.The door cannot be closed unless the trapped key is inserted in the Switch and turned.Opening the door The door can be opened bysupplying power to the Switch solenoid without operating thelockout switch.The door can never be opened without both supplying power to the Switch solenoid andoperating the trapped key.G L Note:designed so that they cannot be turnedcounter-clockwise using a flat-head screwdriver.Read and Understand This CatalogPlease read and understand this catalog before purchasing the products. Please consult your OMRON representative if you have any questions orcomments.WARRANTYOMRON's exclusive warranty is that the products are free from defects in materials and workmanship for a period of one year (or other period if specified) from date of sale by OMRON.OMRON MAKES NO WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, REGARDING NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR PARTICULAR PURPOSE OF THE PRODUCTS. ANY BUYER OR USER ACKNOWLEDGES THAT THE BUYER OR USER ALONE HAS DETERMINED THAT THE PRODUCTS WILL SUITABLY MEET THE REQUIREMENTS OF THEIR INTENDED USE. OMRON DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED.LIMITATIONS OF LIABILITYOMRON SHALL NOT BE RESPONSIBLE FOR SPECIAL, INDIRECT, OR CONSEQUENTIAL DAMAGES, LOSS OF PROFITS OR COMMERCIAL LOSS IN ANY WAY CONNECTED WITH THE PRODUCTS, WHETHER SUCH CLAIM IS BASED ON CONTRACT, WARRANTY, NEGLIGENCE, OR STRICT LIABILITY.In no event shall the responsibility of OMRON for any act exceed the individual price of the product on which liability is asserted.IN NO EVENT SHALL OMRON BE RESPONSIBLE FOR WARRANTY, REPAIR, OR OTHER CLAIMS REGARDING THE PRODUCTS UNLESSOMRON'S ANALYSIS CONFIRMS THAT THE PRODUCTS WERE PROPERLY HANDLED, STORED, INSTALLED, AND MAINTAINED AND NOTSUBJECT TO CONTAMINATION, ABUSE, MISUSE, OR INAPPROPRIATE MODIFICATION OR REPAIR.SUITABILITY FOR USEOMRON shall not be responsible for conformity with any standards, codes, or regulations that apply to the combination of products in the customer's application or use of the products.At the customer's request, OMRON will provide applicable third party certification documents identifying ratings and limitations of use that apply to the products. This information by itself is not sufficient for a complete determination of the suitability of the products in combination with the end product, machine, system, or other application or use.The following are some examples of applications for which particular attention must be given. This is not intended to be an exhaustive list of all possible uses of the products, nor is it intended to imply that the uses listed may be suitable for the products:•Outdoor use, uses involving potential chemical contamination or electrical interference, or conditions or uses not described in this catalog.•Nuclear energy control systems, combustion systems, railroad systems, aviation systems, medical equipment, amusement machines, vehicles, safety equipment, and installations subject to separate industry or government regulations.•Systems, machines, and equipment that could present a risk to life or property.Please know and observe all prohibitions of use applicable to the products.NEVER USE THE PRODUCTS FOR AN APPLICATION INVOLVING SERIOUS RISK TO LIFE OR PROPERTY WITHOUT ENSURING THAT THE SYSTEM AS A WHOLE HAS BEEN DESIGNED TO ADDRESS THE RISKS, AND THAT THE OMRON PRODUCTS ARE PROPERLY RATED AND INSTALLED FOR THE INTENDED USE WITHIN THE OVERALL EQUIPMENT OR SYSTEM.PROGRAMMABLE PRODUCTSOMRON shall not be responsible for the user's programming of a programmable product, or any consequence thereof.CHANGE IN SPECIFICATIONSProduct specifications and accessories may be changed at any time based on improvements and other reasons.It is our practice to change model numbers when published ratings or features are changed, or when significant construction changes are made.However, some specifications of the products may be changed without any notice. When in doubt, special model numbers may be assigned to fix or establish key specifications for your application on your request. Please consult with your OMRON representative at any time to confirm actualspecifications of purchased products.DIMENSIONS AND WEIGHTSDimensions and weights are nominal and are not to be used for manufacturing purposes, even when tolerances are shown.PERFORMANCE DATAPerformance data given in this catalog is provided as a guide for the user in determining suitability and does not constitute a warranty. It may represent the result of OMRON’s test conditions, and the users must correlate it to actual application requirements. Actual performance is subject to the OMRON Warranty and Limitations of Liability.ERRORS AND OMISSIONSThe information in this document has been carefully checked and is believed to be accurate; however, no responsibility is assumed for clerical,typographical, or proofreading errors, or omissions.2010.3In the interest of product improvement, specifications are subject to change without notice. OMRON CorporationIndustrial Automation Company/(c)Copyright OMRON Corporation 2010 All Right Reserved.分销商库存信息:OMROND4GL-2FFA-A D4GL-2DFG-A D4GL-4HFG-A D4GL-4DFG-A。

pp和pet哪个更安全无毒

pp和pet哪个更安全无毒随着环境意识的增强和可持续发展的重要性日益凸显，人们对产品安全性的关注程度也越来越高。

在日常生活中，塑料制品是我们最常接触到的材料之一。

而在塑料制品中，PP和PET两种常见的塑料材料备受关注。

那么，pp和pet哪个更安全无毒？首先，我们需要了解一下PP和PET的特点和用途。

PP（聚丙烯）是一种具有良好热稳定性、机械性能和耐腐蚀性的塑料，常用于制作食品容器、医疗用品、家居用品等。

PET（聚对苯二甲酸乙二酯）是一种透明、坚硬、耐热的塑料，常用于制作饮料瓶、罐头食品容器等。

从安全性角度来看，PP和PET都经过严格的监测和检验，符合食品安全标准。

它们都不含有对人体有害的物质，不会对人体健康产生直接的危害。

同时，它们的生产过程中也遵循环保原则，减少对环境的影响。

因此，从安全无毒的角度来说，无论是PP还是PET，都是可靠的选择。

其次，我们可以从实际应用和使用方面来比较PP和PET的优势。

由于PP具有良好的耐腐蚀性和抗高温性，它在食品包装领域得到了广泛的应用。

而PET则具有透明度高、强度大的特点，被广泛应用于饮料瓶等领域。

根据具体需求，选择PP或PET材料可以更好地满足不同行业的需求。

此外，我们还应考虑到塑料材料的可持续性问题。

在全球塑料污染问题日益严重的背景下，塑料的可持续性成为了人们关注的焦点。

从可持续性角度来看，PP和PET都是可回收利用的塑料材料。

它们可以通过回收再生的方式，减少对环境的负面影响，实现资源的循环利用。

综上所述，pp和pet在安全无毒性方面没有明显差异。

它们都符合食品安全标准，不会对人体健康产生直接的危害。

在实际应用中，可以根据具体需求选择PP或PET材料。

另外，考虑到塑料材料的可持续性，回收利用也是一个重要的考虑因素。

因此，我们不必过分纠结于pp和pet哪个更安全无毒，而是应该在实际应用中选择适合的材料，并积极支持塑料的回收再生。

这样才能实现资源的可持续利用，保护我们的环境和健康。

安全管理论文参考文献

安全管理论文参考文献安全管理是一个旨在保护组织和个人财产、信息和人员免受各种威胁的综合性管理活动。

在当今飞速发展的信息时代，安全管理的重要性越来越凸显出来。

合理有效的安全管理可以帮助组织避免损失，维护业务稳定和社会安定。

下面是一些重要的安全管理领域的论文参考文献。

1. 安全管理的基本原理和框架参考文献•Mayer, R.C., Davis, J.H. and Schoorman, F.D.（1995），“An Integrative Model of Organizational Trust”，Academy of Management Review, Vol. 20No. 3, pp.709-734. - 这篇论文提出了组织信任的综合模型，可作为安全管理的基本原理和框架的参考。

•Zhang, Y.R. and Zhang, H.C.（2011），“A Conceptual Framework for Safety Management System”，Theoretical Issues in Ergonomics Science, Vol. 12 No. 3, pp.209-225. - 这篇论文提出了一个安全管理系统的理论框架，为安全管理实践提供了参考。

2. 安全管理的风险评估和预防措施参考文献•Hale, A.R. and Hovden, J.（1998），“Management and Culture: The Third Age of Safety”，Quality and Safety in Health Care, Vol. 7 No. 2, pp.72-74. - 这篇文章讨论了管理和文化对于安全管理的重要性，并提供了一些风险评估和预防措施的建议。

•Reason, J.（2000），“Human Error: Models and Management”，BMJ, Vol. 320 No. 7237, pp.768-770. - 这篇论文介绍了人为错误的各种模型，并提供了一些管理人为错误的策略。

化学品危险性类别与标志-第1类爆炸品

化学品危险性类别与标志－第1类爆炸品（最新版）编制人：__________________审核人：__________________审批人：__________________编制单位：__________________编制时间：____年____月____日序言下载提示：该文档是本店铺精心编制而成的，希望大家下载后，能够帮助大家解决实际问题。

文档下载后可定制修改，请根据实际需要进行调整和使用，谢谢!并且，本店铺为大家提供各种类型的安全管理制度，如通用安全、交通运输、矿山安全、石油化工、建筑安全、机械安全、电力安全、其他安全等等制度，想了解不同制度格式和写法，敬请关注!Download tips: This document is carefully compiled by this editor. I hope that after you download it, it can help you solve practical problems. The document can be customized and modified after downloading, please adjust and use it according to actual needs, thank you!In addition, this shop provides you with various types of safety management systems, such as general safety, transportation, mine safety, petrochemical, construction safety, machinery safety, electrical safety, other safety, etc. systems, I want to know the format and writing of different systems ,stay tuned!化学品危险性类别与标志－第1类爆炸品化学品作为一种特殊的商品，极大地改善了人们的生活，但其固有的特性如爆炸性、燃烧性、腐蚀性、毒害性、氧化性、放射性和反应性，等等，也给人类的生存带来了极大的威胁。

MSDS-PP聚丁烯

MSDS-PP聚丁烯产品概述本文档为MSDS-PP聚丁烯的安全数据表（Material Safety Data Sheet）。

聚丁烯是一种常用的塑料材料，具有可塑性、耐风化性和耐化学性等特点。

成分信息- 化学品名称：PP聚丁烯- 化学式：(C4H8)n- CAS号：9003-22-9- 外观和性状：无色颗粒或颗粒状理化性质- 溶解性：不溶于水，可溶于热的芳烃、酮类和酯类溶剂。

- 熔点：160-168°C- 相对密度：0.855-0.946 g/cm3（25°C）- 燃烧性：聚丁烯属于可燃物质，遇明火可燃烧。

危险性评估- 健康危害：长期暴露可能导致呼吸系统刺激，可能对肺部产生损害。

- 环境危害：未经处理的废弃物可能对环境造成负面影响。

- 燃烧产物：燃烧时可能释放有害烟雾和气体，如二氧化碳和一氧化碳。

防护措施- 呼吸系统防护：在粉尘浓度较高的环境下，应佩戴防颗粒物呼吸器。

- 眼睛防护：避免接触眼睛，如有意外溅入眼睛，立即用大量清水冲洗至少15分钟，必要时就医。

- 皮肤防护：应穿戴适当的防护服和手套，避免长时间接触聚丁烯。

- 环境防护：避免将废弃物排入水体或土壤。

应急措施- 食入：不小心吞食了聚丁烯，立即给患者大量饮水，如果出现不适，请立即就医。

- 眼睛接触：如聚丁烯进入眼睛，立即用大量清水冲洗至少15分钟，必要时就医。

- 皮肤接触：应用大量流动的清水冲洗。

储存和运输- 储存：应储存在干燥、通风的仓库中，避免阳光直射。

- 运输：运输时应注意防止受潮、曝晒，防止与酸、碱等物质混合。

废弃物处理- 废弃物处理：遵循当地环境法规，应将废弃的聚丁烯进行分类并正确处理。

- 废弃包装物处理：经彻底清洗后，可回收利用或按环保要求进行处理。

急救措施注意事项- 急救人员应注意自身安全。

- 如证实吸入过量粉尘或湿蒸气，应将患者移至空气流通处。

- 如出现皮肤红肿、灼痛等不适症状，应立即脱离接触源，进行洗净。

PP聚丙烯安全资质资料表_MSDS

PP聚丙烯安全资质资料表_MSDS PP聚丙烯安全资质资料表,MSDS,第一部分:化学品名称化学品中文名称:聚丙烯(等规)化学品英文名称: Polypropylene中文名称2: PP料英文名称2: PPCAS No.: 9003-07-0分子式: [CH]n 36分子量: NA第二部分:成分/组成信息有害物成分: 无含量: 100%CAS No.: 9003-07-0第三部分:危险性概述危险性类别:不详侵入途径:吸入健康危害:本身无毒, 注意不同添加剂的毒性。

热解产物酸、醛等对眼、上呼吸道有刺激作用。

环境危害:在土壤中不能分解燃爆危险:本品可燃。

第四部分:急救措施吸入:脱离现场至空气新鲜处。

如呼吸困难，给输氧。

就医。

第五部分:消防措施危险特性:粉体与空气可形成爆炸性混合物, 当达到一定浓度时, 遇火星会发生爆炸。

加热分解产生易燃气体。

有害燃烧产物:一氧化碳、二氧化碳。

灭火方法:尽可能将容器从火场移至空旷处。

灭火剂:雾状水、泡沫、干粉、二氧化碳、砂土。

第六部分:泄漏应急处理应急处理:隔离泄漏污染区，限制出入。

切断火源。

建议应急处理人员戴防尘面具(全面罩)，穿一般作业工作服。

用洁净的铲子收集于干燥、洁净、有盖的容器中，转移至安全场所。

若大量泄漏，收集回收或运至废物处理场所处置。

第七部分:操作处置与储存操作注意事项:密闭操作。

密闭操作，提供良好的自然通风条件。

操作人员必须经过专门培训，严格遵守操作规程。

建议操作人员佩戴自吸过滤式防尘口罩。

远离火种、热源，工作场所严禁吸烟。

使用防爆型的通风系统和设备。

避免与氧化剂接触。

搬运时要轻装轻卸，防止包装及容器损坏。

配备相应品种和数量的消防器材及泄漏应急处理设备。

倒空的容器可能残留有害物。

储存注意事项:储存于阴凉、通风的库房。

远离火种、热源。

应与氧化剂分开存放，切忌混储。

配备相应品种和数量的消防器材。

储区应备有合适的材料收容泄漏物。

第八部分:接触控制/个体防护职业接触限值中国MAC(mg/m3):10 前苏联MAC(mg/m3):10TLVTN:未制定标准 TLVWN:未制定标准监测方法:工程控制:密闭操作。

安全环保专业名词缩写

最全的健康安全环保专业名词缩写、词典清单作为一个EHS管理人员必须掌握的一些健康安全环保英文、专业名词等，请收藏：1.常用健康安全环保英文缩写清单序号英文缩写英文全称中文翻译1 HSE Health Safety Environment 健康安全环保2 FI Fatal Injury 死亡事故3 LTI Lost Time Injury 损失工作日事故4 MI Medical Injury 医疗救助事故5 FA First Aid Injury 急救事故6 NM Near-Miss Incident 险兆事故7 LWD Lost Work Day 损失工作天数8 LTIFR Lost Time Injury Frequency Rate 损失工作日事故频率9 SR Serious Rate 事故严重率10 SER Serious Event Review 严重事件评审11 RCA Root Cause Analysis 根本原因分析12 MSDS Material Safety Data Sheet 危险化学品安全技术说明书13 COD Chemical Oxygen Demand 化学需氧量14 BOD Biochemical Oxygen Demand 生化需氧量15 SS Suspended Substance 悬浮物16 PH Potential of Hydrogen PH值（氢离子浓度指数）17 PPE Personalprotective equipment个人防护用品（装备）18 VFL Visible Felt Leadership 可视可感领导力19 RA Risk Analysis 风险分析20 JHA Job Hazard Analysis 工作风险分析21 JSA Job Safety Analysis 工作安全分析22 HOC Hierarchy Of Controls 控制措施优先次序23 WAH Work At Height 高空作业24 LIFT LIFT 起重作业25 ME Mobile Equipment 移动设备26 CSA Corrective Safety Action 紧急行动计划27 LOTO Lock Out & Tag Out 上锁挂牌28 LOTOTO Lock Out & Tag Out & Try Out 上锁挂牌验证29 WBGT Wet & Black Globe Temperature 湿球黑球温度30 LGSS LiuGong Safety standard 柳工安全标准库(含健康环保)31 EI Energy Isolation 能量隔离32 PTW Permit To Work 作业许可33 HERA Hazard Energy Risk Analysis 危险能量风险分析34 HECP Hazard Energy Control Process 危险能量控制程序35 STOP Safety-Training-Observation- Programme 安全-培训-观察-程序36 CSM Contractor Safety Management 合同方安全管理37 TWA Time Weighted Average 时间加权平均38 PC-TWA Permissible concentration-Time WeightedAverage时间加权平均容许浓度39 STEL Short Term Exposure Limit 短期接触限值40 PC-STEL Permissible concentration-Short TermExposure Limit短期接触容许浓度41 WBC White Blood Cell 白细胞42 RBC Red Blood Cell 红细胞43 PLT Platelet 血小板44 HB Hemoglobin 血红蛋白45 TCH Total Cholesterol 总胆固醇46 TG Triglyceride 甘油三酯47 HDL High Density Lipoprotein 高密度脂蛋白48 ALT/GPT Alanine amiotransferase/Glutamic-Pyruvic Transaminase谷丙转氨酶49 AST/GOT Aspartatetransaminase/Glutamic-Oxal(o)acetic Transaminase谷草转氨酶50 AFP A-fetoprotein 甲胎蛋白51 HbsAg Hepatitis B surface Antigen 乙肝表面抗原52 HbsAb Hepatitis B surface Antibody 乙肝表面抗体2.常用健康安全环保专业名词序号英文翻译中文名词缩写1 Occupational disease 职业病2 Suspicious Occupational disease 疑似职业病3 Occupational Observation Object 职业观察对象4 Pneumoconiosis 尘肺病5 Occupational benzene poisoning 职业性苯中毒6 Occupational noise deaf 职业性噪声聋7 Occupational hazard 职业病危害8 Occupational Contraindication 职业禁忌症9 Dust Medical Observation Object (alsocalled 0+)粉尘作业医学观察对象（旧称0+）O+10 High Manganese in Urine 尿锰偏高11 High Chromium in Urine 尿铬偏高12 Low WBC (White Blood Cell) 白细胞偏低13 Hearing Loss Observation Object 听力损失观察对象14 Hemorrheology check 血流变检查15 Qualified Rate of Dust Poisition 尘毒点合格率16 Environmental Pollution Accident 环境污染事故17 Smoke Dust 烟尘18 Sulfur Dioxide 二氧化硫SO219 Nitrogen Oxides 氮氧化物20 Ringelmann Blackness 林格曼黑度21 Dust 粉尘22 Hexavalent Chromium 六价铬Cr6+23 Waste Water 废水24 Waste Air 废气25 Noise 噪声26 Dangerous Solid Waste 危险废弃物27 Benzene 苯28 Methylbenzene 甲苯29 Xylene 二甲苯3.健康安全环保词典序号英文翻译中文名词缩写1 Hazard 危险2 Safety 安全3 Risk 风险4 Hazardous Source 危险源5 Environmental Factor 环境因素6 National Production Safety Policy 国家安全生产方针7 Three Violations of Rules in Safety 三违8 Four Principles of No Harm 四不伤害9 Four Principles for Accident/Incidentinvestigation and Record四不放过10 Four New Technology 四新11 Five Simultaneousness System ofProduction Safety生产安全“五同时”12 Fatal Injury 死亡事故FI13 Lost Time Injury 损失工作日事故LTI14 Medical Injury 医疗救助事故MI15 First Aid Injury 急救事故FA16 Near-Miss Incident 险兆事故NM17 Total Working Hours of LiuGongEmployees公司员工工作小时总数18 Lost Work Day 损失工作日天数LWD19 LiuGong Employee 柳工公司员工20 Contractor Employee 合同方员工21 Third-party Employee 第三方员工22 Lost Time Injury Frequency Rate 损失工作日事故频率LTIFR23 Serious Rate 事故严重率SR24 Medical Injury Frequency Rate 医疗救助事故频率MIFR25 Total Injury Frequency Rate 总伤害频率TIFR26 Personal protective equipment 劳动防护用品PPE27 Mandatory Personal protective equipment 强制性劳动防护用品28 Safety Shoes 安全鞋29 Safety Hamlet 安全帽30 High Vsibility Clothing 高可见度服装31 Basic Personal protective equipment 基本劳动防护用品32 Head Protective Equipment 头部护具类33 Respirator Equipment 呼吸护具类34 Glass/Mask Protecitve Equipment 眼（面）护具类35 Protective Clothing 防护服类36 Protective Shoes 防护鞋类37 Fall-off Protective Equipment 防坠落护具类38 Elimination 消除39 Alternative Measure 替代措施40 Isolation Measure 隔离措施41 Project Measure 工程措施42 Management Measure 管理措施43 Hoist and Crane Equipment Safety 起重机械安全44 Hoist and Crane Equipment 起重机械45 Transformation & Movement 改造和移动46 Overhaul 大修47 Special Equipment 特种设备48 Boiler 锅炉49 Pressure Vessel 压力容器50 Pressure Pipeline 压力管道51 Elevator 电梯52 Field (Plant) Exclusive Vehicle 场（厂）内专用机动车辆53 Special Equipment Operator 特种设备操作人员54 Special Task Personnel 特种作业人员55 Special Task 特种作业56 Three Simulataneousness System ofConstruction Project建设项目“三同时”57 Three Simulataneousness 三同时58 Pre Evaluation of Occuptional DiseaseHarm职业病危害预评价59 Occupation hazards control effect evaluation 职业病危害控制效果评价60 Environmental Impact Assessment 环境影响评价EIA61 Safety Assessment Prior to Start 安全预评价62 Safety Assessment Upon Completion 安全验收评价63 Occupational Disease 职业病64 Pneumoconiosis Medical ObservationObject尘肺医学观察对象65 Three Level Prevention of OccupationDisease职业病的三级预防66 Occupational Harm Factor 职业性的有害因素67 Productive Toxictant 生产性毒物68 Productive Dust 生产性粉尘69 Occupational Poisoning 职业中毒70 Occupational Contraindication 职业禁忌71 Hot Work 高温作业72 Cold Work 低温作业73 Common Occupational Disease 常见职业病74 Pneumoconiosis 尘肺病75 Silicosis 矽肺病76 Welder’s Pneumoconiosis 电焊工尘肺77 Occupational Noise Deafness 职业性噪声性耳聋78 Hand-arm Vibration Syndrome 手臂振动病79 Electric Ophthalmia 电光性眼炎80 Benzene Poisoning 苯中毒81 Chromeulcer 铬疮82 Manganese Poisoning 锰中毒83 Heatstroke 中暑84 Painting Task Low WBC 油漆作业白细胞偏低85 Hemorrheology Check 血流变检查86 Dust Task Hemorrheology Check 粉尘作业血流变异常87 Environmental Protection 环境保护88 Environmental Protection Facilities 环保设备89 Clearer Production 清洁生产90 Clearer Energy 清洁能源91 Cyclic Economy 循环经济92 Low Cabin Economy 低碳经济93 Greenhouse Effect 温室效应94 Plastic Pollution 白色污染95 Primary Pollutant 一次污染物96 Secondary Pollutant 二次污染物97 Acid Rain 酸雨98 “Three Wastes” “三废”99 Solid Waste 废弃物100 P hysical Treatment 物理处理101 C hemical Treatment 化学处理102 R eclaimed Water Reuse Technology 中水回用技术103 A eration 曝气104 R ingelmann Blackness 林格曼黑度105 P otential of Hydrogen pH值pH 106 S uspended Substance 水质中的悬浮物SS 107 C hemical Oxygen Demand 化学含氧量COD 108 B iochemical Oxygen Demand 生物含氧量BOD5 109 G ravitate Dust Filter 重力除尘器110 C yclone Dust Filter 旋风除尘器111 B ag Dust Filter 袋式除尘器112 W et Dust Filter 湿法除尘器。

pp无纺布MSDS报告

物質安全資料表Material Safety Data Sheet一、物品名稱與廠商資料Identification of the substance/preparation and company物質名稱Product Information无纺布Nonwoven物品編號Product Number：****製造商或供應商名稱地址及電話Information on Producer/Supplier Name、Addresses、Phone: ***電話：***傳真：***緊急聯絡電話/傳真電話Emergency Phone/Fax:電話：***傳真：***製表單位Make Unit 名稱Name:廠務部製表日期Make date***地址/電話Addresses/Phone:***電話：***製表人Make People 職稱Professional Post:***姓名Name(Sign):***文件編號Document No.版次Version1.0文件類別Document typeUncontrolled Document二、成分辨識資料Composition/Information on Ingredients純物質Single中英文名稱English Name:无纺布Nonwoven同義名稱Synonyms:PP Nonwoven化學文摘社登記號碼Chemical abstracts Number(CAS No.):PP CAS NO:9003-07-0;危害物質萬分百分比Percentage for Chemical Ingredient(%):混合物Mixing:化學性質Chemical Character:酸性Acid危害物質萬分之中英文名稱Hazardous Components Name 濃度或濃度範圍（成分百分比）Concentration/Percentage危害物質分類及圖式Hazard Symbols染料1PP99三、危害辨識資料Hazard Identification:最重要危害效應Major Hazard Effect：無健康危害效應：沒有Hazard Warnings for Health:環境影響：沒有Hazard Warnings for Environment:物理性及化學性危害：沒有Physical and Chemical Dangerous:特殊危害Special Harm:沒有主要症狀Major State:無物品危害分類Hazard Category:四、急救措施First Aid Measures:不同暴露途徑之急救方法Emergency and First Aid Procedures●吸入Inhalation：熱加工時產生的氣體煙霧可能刺激口鼻呼吸道●皮膚接觸Skin Contact：產品在高溫或溶化時，皮膚接觸會灼傷，必須用大量清水沖洗不可強行剝離。